Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Acquired by GAM Holding AG

by · The Cerbat Gem

GAM Holding AG boosted its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report) by 42.8% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 12,320 shares of the medical research company’s stock after purchasing an additional 3,695 shares during the quarter. GAM Holding AG’s holdings in Thermo Fisher Scientific were worth $6,130,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. Stonegate Investment Group LLC boosted its position in Thermo Fisher Scientific by 6.5% during the 1st quarter. Stonegate Investment Group LLC now owns 7,231 shares of the medical research company’s stock valued at $3,598,000 after purchasing an additional 443 shares during the period. Worth Financial Advisory Group LLC boosted its position in Thermo Fisher Scientific by 283.5% during the 1st quarter. Worth Financial Advisory Group LLC now owns 1,603 shares of the medical research company’s stock worth $798,000 after acquiring an additional 1,185 shares during the period. PFG Investments LLC boosted its position in Thermo Fisher Scientific by 4.0% during the 1st quarter. PFG Investments LLC now owns 2,222 shares of the medical research company’s stock worth $1,106,000 after acquiring an additional 86 shares during the period. Canoe Financial LP acquired a new position in Thermo Fisher Scientific during the 1st quarter worth $3,981,000. Finally, Rockline Wealth Management LLC boosted its position in Thermo Fisher Scientific by 9.2% during the 1st quarter. Rockline Wealth Management LLC now owns 1,669 shares of the medical research company’s stock worth $830,000 after acquiring an additional 140 shares during the period. Institutional investors and hedge funds own 89.23% of the company’s stock.

Insider Activity

In other news, EVP Gianluca Pettiti sold 300 shares of Thermo Fisher Scientific stock in a transaction on Monday, April 28th. The stock was sold at an average price of $429.93, for a total transaction of $128,979.00. Following the transaction, the executive vice president now owns 23,167 shares in the company, valued at approximately $9,960,188.31. The trade was a 1.28% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 0.33% of the stock is currently owned by corporate insiders.

Thermo Fisher Scientific Stock Performance

Shares of NYSE TMO opened at $397.31 on Friday. The company has a quick ratio of 1.38, a current ratio of 1.77 and a debt-to-equity ratio of 0.64. The stock has a market capitalization of $149.98 billion, a price-to-earnings ratio of 23.30, a PEG ratio of 2.07 and a beta of 0.78. The stock’s fifty day simple moving average is $412.62 and its 200 day simple moving average is $487.84. Thermo Fisher Scientific Inc. has a 52-week low of $385.46 and a 52-week high of $627.88.

Thermo Fisher Scientific (NYSE:TMO – Get Free Report) last issued its earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.10 by $0.05. Thermo Fisher Scientific had a return on equity of 17.15% and a net margin of 15.19%. The business had revenue of $10.36 billion for the quarter, compared to analysts’ expectations of $10.23 billion. During the same period in the previous year, the firm posted $5.11 EPS. The company’s quarterly revenue was up .2% on a year-over-year basis. As a group, sell-side analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, July 15th. Stockholders of record on Friday, June 13th will be issued a dividend of $0.43 per share. The ex-dividend date is Friday, June 13th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.43%. Thermo Fisher Scientific’s dividend payout ratio is 10.09%.

Analyst Ratings Changes

TMO has been the subject of a number of analyst reports. UBS Group reduced their price target on Thermo Fisher Scientific from $715.00 to $500.00 and set a “buy” rating for the company in a research report on Thursday, April 24th. Barclays reduced their price target on Thermo Fisher Scientific from $620.00 to $475.00 and set an “equal weight” rating for the company in a research report on Thursday, April 10th. Royal Bank Of Canada reduced their price target on Thermo Fisher Scientific from $651.00 to $637.00 and set an “outperform” rating for the company in a research report on Thursday, April 24th. Citigroup dropped their price objective on Thermo Fisher Scientific from $650.00 to $570.00 and set a “neutral” rating on the stock in a research note on Tuesday, March 4th. Finally, Wall Street Zen raised Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research note on Wednesday, May 21st. Four investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $605.30.

Check Out Our Latest Stock Analysis on TMO

Thermo Fisher Scientific Profile

(Free Report)

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

See Also

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report).